CN105560264A - Composition containing cobamamide - Google Patents
Composition containing cobamamide Download PDFInfo
- Publication number
- CN105560264A CN105560264A CN201610138133.4A CN201610138133A CN105560264A CN 105560264 A CN105560264 A CN 105560264A CN 201610138133 A CN201610138133 A CN 201610138133A CN 105560264 A CN105560264 A CN 105560264A
- Authority
- CN
- China
- Prior art keywords
- cobamamide
- folic acid
- megaloblastia
- treating
- anemia
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7135—Compounds containing heavy metals
- A61K31/714—Cobalamins, e.g. cyanocobalamin, i.e. vitamin B12
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses a composition containing cobamamide. The composition is prepared from the following ingredients in parts by weight: 3 to 9 parts of cobamamide and 1 to 2 parts of folic acid. Due to the fact that the cobamamide has an unobvious treatment effect in treating megaloblastia anemia caused by lack of the folic acid and is limited in the clinic application of treating megaloblastia anemia, through a lot of experiments, the folic acid is added in the cobamamide according to a limit ratio and is mixed with the cobamamide, a prepared medicine composition is not only used for keeping an original effect of the cobamamide for treating conventional megaloblastia anemia, but also has a very good effect for treating megaloblastia anemia caused by the lack of the folic acid, so that the clinic application range of the cobamamide is broadened.
Description
Technical field
The present invention relates to technical field of medicine, be specifically related to a kind of compositions containing cobamamide.
Background technology
Cobamamide, chemical name: 5,6-dimethylbenzimidazole base-5'-deoxyadenosine base cobalt amine; English name: Cobamamide.Cobamamide is mainly used in megaloblastic anemia, malnutritional anemia, anemia in pregnancy, also for neurological disorder as polyneuritis, radiculitis, trigeminal neuralgia, sciatica, neural paralysis, trophic nerve illness and lonizing radiation and drug-induced leukopenia.
Cobamamide has applied range, feature safely and effectively, stronger therapeutical effect is had especially for anemic disorders such as megaloblastic anemia, malnutritional anemia, anemias in pregnancy, but in treatment because the therapeutic effect of the megaloblastic anemia caused by folic acid deficiency is not obvious.
Summary of the invention
The object of the invention is to overcome the deficiencies in the prior art, a kind of pharmaceutical composition containing cobamamide can treated because of the megaloblastic anemia caused by folic acid deficiency is provided.
To achieve these goals, the present invention adopts following technical scheme:
Containing a compositions for cobamamide, be made up of the component of following weight portion:
Cobamamide 3 ~ 9;
Folic acid 1 ~ 2;
Its preferred parts by weight are:
Cobamamide 5;
Folic acid 1;
Dosage form and the preparation method of compositions of the present invention are not particularly limited, and the conventional general method for making in available this area makes the various peroral dosage form such as tablet, capsule.
Compared with prior art, the present invention has following beneficial effect: in view of cobamamide is for treating because the therapeutic effect of the megaloblastic anemia caused by folic acid deficiency is not obvious.Clinical practice in this is restricted, the present invention is through great many of experiments, folic acid and its mixture is added according to restriction ratio in cobamamide, obtained pharmaceutical composition is except after the conventional megaloblastic anemia of the maintenance original treatment of cobamamide, also there is good effect to because of the megaloblastic anemia caused by folic acid deficiency, thus widened the clinical application range of cobamamide.
Detailed description of the invention
Embodiment 1:
The weight ratio of pressing 3:1 of cobamamide and folic acid is mixed, obtained pharmaceutical composition, make oral tablet by the conventional general method for making in this area.
Embodiment 2:
Checking:
1. case
40 routine patients, are women, and be divided into treatment group (cobamamide+folic acid) and each 20 examples of matched group (cobamamide) at random, at two groups of ages, the aspects such as the state of an illness compare no significant difference.
2. method
The oral the present embodiment 1 for the treatment of group makes oral tablet, each 0.5mg, and every day sooner or later respectively once.
The oral cobamamide sheet of matched group, each 0.5mg, every day sooner or later respectively once.
Each patient is one month whole course for the treatment of.
3. result
Can be drawn by upper table data: cobamamide to because of the therapeutic effect of the megaloblastic anemia caused by folic acid deficiency not obvious, and embodiment 1 to because of the therapeutic effect of the megaloblastic anemia caused by folic acid deficiency obvious.
Claims (2)
1., containing a compositions for cobamamide, it is characterized in that: be made up of the component of following weight portion: cobamamide 3 ~ 9, folic acid 1 ~ 2.
2. a kind of compositions containing cobamamide as described in right 1, is characterized in that: its preferred parts by weight are: cobamamide 5, folic acid 1.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610138133.4A CN105560264A (en) | 2016-03-11 | 2016-03-11 | Composition containing cobamamide |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610138133.4A CN105560264A (en) | 2016-03-11 | 2016-03-11 | Composition containing cobamamide |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN105560264A true CN105560264A (en) | 2016-05-11 |
Family
ID=55871283
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610138133.4A Pending CN105560264A (en) | 2016-03-11 | 2016-03-11 | Composition containing cobamamide |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105560264A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108186668A (en) * | 2018-01-23 | 2018-06-22 | 广东伊茗药业有限公司 | A kind of composition containing cobamamide |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1518554A1 (en) * | 2003-09-26 | 2005-03-30 | Medosan Industrie Biochimiche Riunite S.r.l. | Pharmaceutical composition for the treatment of hyperhomocysteinemia |
| CN102379851A (en) * | 2010-09-03 | 2012-03-21 | 华北制药股份有限公司 | Preparation method of cobamamide lyophilized preparation for injection |
-
2016
- 2016-03-11 CN CN201610138133.4A patent/CN105560264A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1518554A1 (en) * | 2003-09-26 | 2005-03-30 | Medosan Industrie Biochimiche Riunite S.r.l. | Pharmaceutical composition for the treatment of hyperhomocysteinemia |
| CN102379851A (en) * | 2010-09-03 | 2012-03-21 | 华北制药股份有限公司 | Preparation method of cobamamide lyophilized preparation for injection |
Non-Patent Citations (4)
| Title |
|---|
| B.FOWLER ET AL.: ""Folate-responsive homocystinuria and megaloblastic anaemia in a female patient with functional methionine synthase deficiency (cblE disease)"", 《J.INHER.METAB.DIS》 * |
| 张庆宪: "《常用新药精汇手册》", 28 February 2009, 河南科学技术出版社 * |
| 胡家露,樊代明: "《内科学》", 31 August 2001, 高等教育出版社 * |
| 霍宏俊等: ""不同高剂量叶酸及叶酸与腺苷钴胺片联合治疗高HCY血症疗效观察"", 《中国继续医学教育》 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108186668A (en) * | 2018-01-23 | 2018-06-22 | 广东伊茗药业有限公司 | A kind of composition containing cobamamide |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN108939080A (en) | The purposes of composition containing tyrosine kinase inhibitor and resveratrol in the preparation of antitumor drugs | |
| Deshmukh et al. | Effectiveness of combinations of Ayurvedic drugs in alleviating drug toxicity and improving quality of life of cancer patients treated with chemotherapy | |
| CN105560264A (en) | Composition containing cobamamide | |
| HRP20201608T1 (en) | Synergistic compositions comprising (r)-dimiracetam (1) and (s)-dimiracetam (2) in a non-racemic ratio | |
| CN106177497A (en) | A kind of antitumor drug and preparation method thereof | |
| CN103417521B (en) | Application of 3,4-Dihydroxyphenylacetic acid in preparing antitumor drug | |
| CN106237268A (en) | One treats schizoid pharmaceutical composition and application thereof | |
| CN107126508A (en) | A kind of pharmaceutical composition for preventing and treating senile dementia and preparation method thereof | |
| CN101342143A (en) | Preparation of antineoplastic drug docetaxel injection | |
| CN109248171A (en) | Composition containing Imatinib and plant polyose | |
| CN103110949A (en) | Ribavirin small-capacity injection preparation and preparation method thereof | |
| CN103055002A (en) | Composition for treating respiratory disease of poultry and preparation method thereof | |
| CN102511824A (en) | Antimutation and antitumor functional foodstuff | |
| CN103070940A (en) | Nutritional health-care product for improving menopausal symptoms | |
| CN106822764A (en) | For treating the leukemogenic compound Chinese medicinal preparation of deficiency of spleen-QI and stomach-QI institute and preparation method | |
| CN101947224B (en) | Stomach medicament | |
| Edelman | Gemcitabine and Carboplatin Regimens in Advanced Non–Small-Cell Lung Cancer: Focus on Randomized Phase III Trials | |
| Li et al. | The Synergistic Antidepressant Effect: Compatibility of Alkaloids with Saponins from Ziziphi Spinosae Semen | |
| CN107441219B (en) | Pharmaceutical composition for improving immune function of acquired immune deficiency syndrome and application thereof | |
| Jankar et al. | REVIEW ON CHANDANADI LAUHA | |
| CN108186668A (en) | A kind of composition containing cobamamide | |
| CN105769884A (en) | Medicine composition for treating lung cancer | |
| CN104414969A (en) | Compound fluorouracil injection and preparation method thereof | |
| CN102579499A (en) | Huachansu dripping pill and preparation method thereof | |
| CN115025193A (en) | Traditional Chinese medicine composition for treating tumor-related insomnia and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20160511 |
|
| RJ01 | Rejection of invention patent application after publication |